CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
58.78
+2.28 (4.04%)
At close: Mar 9, 2026, 4:00 PM EDT
56.53
-2.25 (-3.83%)
After-hours: Mar 9, 2026, 7:58 PM EDT

CRISPR Therapeutics AG Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-581.6-366.25-153.61-650.18377.66
Upgrade
Depreciation & Amortization
19.4819.2619.8424.1717.95
Upgrade
Asset Writedown & Restructuring Costs
96.25-2.5--
Upgrade
Stock-Based Compensation
72.586.5781.0397.95102.39
Upgrade
Other Operating Activities
-23.53-38.62-16.5512.4714.11
Upgrade
Change in Accounts Receivable
25175-2000.31-0.16
Upgrade
Change in Accounts Payable
44.89-27.28-20.255.1637.51
Upgrade
Change in Unearned Revenue
-0.4-1.955.79-1.01-0.78
Upgrade
Change in Other Net Operating Assets
2.3910.520.8715.39-9.71
Upgrade
Operating Cash Flow
-345.01-142.77-260.38-495.74538.97
Upgrade
Capital Expenditures
-0.91-1.9-9.47-37.19-81.71
Upgrade
Sale (Purchase) of Intangibles
-25--2.5--
Upgrade
Investment in Securities
-5.89-278.58386.62-221.47-953.73
Upgrade
Investing Cash Flow
-31.81-280.48374.65-258.66-1,035
Upgrade
Issuance of Common Stock
426.03331.9862.6638.59250.95
Upgrade
Financing Cash Flow
426.03331.9862.6638.59250.95
Upgrade
Foreign Exchange Rate Adjustments
0.1-0.020.07-0.08-0.01
Upgrade
Miscellaneous Cash Flow Adjustments
---0--
Upgrade
Net Cash Flow
49.3-91.29177.01-715.88-245.52
Upgrade
Free Cash Flow
-345.93-144.68-269.85-532.93457.27
Upgrade
Free Cash Flow Margin
-9855.50%-387.72%-72.69%-44484.89%49.98%
Upgrade
Free Cash Flow Per Share
-3.85-1.72-3.41-6.865.69
Upgrade
Levered Free Cash Flow
-205.62-29.27-238.97-337.58284.82
Upgrade
Unlevered Free Cash Flow
-205.62-29.27-238.97-337.58284.82
Upgrade
Change in Working Capital
71.88156.27-193.5919.8526.86
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.